Please wait while the formulary information is being retrieved.
VIDEX EC (DIDANOSINE)
- HIV infection
125 mg capsule,delayed release
- 2 capsules (250 mg) by oral route once daily 1/2 hour before a meal or 2 hours after a meal
200 mg capsule,delayed release
- 2 capsules (400 mg) by oral route once daily 1/2 hour before a meal or 2 hours after a meal
250 mg capsule,delayed release
- 1 capsule (250 mg) by oral route once daily 1/2 hour before a meal or 2 hours after a meal
125 mg capsule,delayed release
- 2 capsules (250 mg) by oral route once daily 1/2 hour before a meal or 2 hours after a meal
200 mg capsule,delayed release
- 2 capsules (400 mg) by oral route once daily 1/2 hour before a meal or 2 hours after a meal
250 mg capsule,delayed release
- 1 capsule (250 mg) by oral route once daily 1/2 hour before a meal or 2 hours after a meal
400 mg capsule,delayed release
- 1 capsule (400 mg) by oral route once daily 1/2 hour before a meal or 2 hours after a meal
HIV infection
- 1 capsule (250 mg) by oral route once daily 1/2 hour before a meal or 2 hours after a meal
- 2 capsules (250 mg) by oral route once daily 1/2 hour before a meal or 2 hours after a meal
- 2 capsules (400 mg) by oral route once daily 1/2 hour before a meal or 2 hours after a meal
- allopurinol
- allopurinol sodium
- Aloprim
- Copegus
- Moderiba
- Moderiba Dose Pack
- organ preservation soln no.3
- Rebetol
- Ribapak Dose Pack
- Ribasphere
- Ribatab Dose Pack
- ribavirin
- Viaspan (belzer Uw) Cold Ss
- Virazole
- Zyloprim
Contraindicated
- Droxia
- Hydrea
- hydroxyurea
- stavudine
- Zerit
Severe
Moderate
- Atripla
- Complera
- Crixivan
- darunavir
- delavirdine
- Diskets
- Dolophine
- Edurant
- efavirenz-emtricitabin-tenofov
- elvitegr-cobicist-emtric-tenof
- emtricitab-rilpivirine-tenofov
- emtricitabine-tenofovir
- indinavir
- Kaletra
- lopinavir-ritonavir
- methadone
- Methadone Intensol
- Methadose
- Prezista
- Rescriptor
- rilpivirine
- Stribild
- tenofovir disoproxil fumarate
- Truvada
- Viread
- Lactating mother
- Lactic acidosis
- Pancreatitis
- Steatosis of liver
Contraindicated
- Alcoholism
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Disease of liver
- Optic neuritis
- Peripheral neuropathy
- Portal hypertension
Severe
Moderate
- Coronary artery disease
- Diabetes mellitus
- Hypercholesterolemia
- Hypertension
- Hypertriglyceridemia
- Hyperuricemia
- Increased cardiovascular event risk
- Kidney disease with likely reduction in GFR
- Obesity
- Tobacco smoker
VIDEX EC (DIDANOSINE)
- HIV infection
- Peripheral neuropathy
- Abdominal pain with cramps
- CNS toxicity
- Diarrhea
- Dyspepsia
- Headache disorder
- Lipodystrophy associated with HIV
- Nausea
- Vomiting
- Xerostomia
More Frequent
Severe
Less Severe
- Acute pancreatitis
- Hyperbilirubinemia
- Severe diarrhea
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Anemia
- Cardiomyopathy
- Drug-induced hepatitis
- Hepatitis
- Hyperuricemia
- Lactic acidosis
- Leukopenia
- Optic neuritis
- Pigmentary retinopathy
- Portal hypertension
- Pruritus of skin
- Seizure disorder
- Skin rash
- Steatosis of liver
- Thrombocytopenic disorder
Less Severe
- Alopecia
- Chills
- Fever
- General weakness
- Pain
Contraindicated
None
Severe Precaution
Didanosine
Not recommended < age 14 days. Highly variable drug levels. Reports of optic neuritis, retinal changes and pancreatitis.
- 1 Day – 13 Days
- Not recommended < age 14 days. Highly variable drug levels. Reports of optic neuritis, retinal changes and pancreatitis.
Management or Monitoring Precaution
Didanosine
Monitor for pancreatitis. Consider periodic retinal exam.
- 14 Days – 18 Years
- Monitor for pancreatitis. Consider periodic retinal exam.
Didanosine
- Severity Level:
2
- Additional Notes: Caution; fatal lactic acidosis reported when used with other antiretrovirals
Contraindicated
Didanosine
Cdc does not recommend breastfeeding in hiv-positive women
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Rarely, didanosine has caused a severe (sometimes fatal) pancreas problem (pancreatitis) when used alone or with other HIV medicines. Immediately tell your doctor if you develop symptoms of pancreatitis (persistent nausea/vomiting, stomach/abdominal/back pain). Rarely, didanosine has caused a severe (sometimes fatal) liver and blood problem (lactic acidosis).<br /><br />These problems may be more likely in females or people who are overweight (obese). Immediately tell your doctor if you develop symptoms of liver problems (persistent nausea, stomach/abdominal pain, dark urine, yellowing eyes/skin) or lactic acidosis (rapid breathing, drowsiness, muscle aches, severe weakness). Didanosine should not be used with a certain HIV medicine, stavudine, due to increased risk of these serious side effects.
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
| 0-9 | A-Z |
|---|---|
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool